Lanifibranor meets efficacy, safety endpoints in phase 2b NASH trial

Inventiva announced lanifibranor met primary and secondary endpoints in a phase 2b study for treatment of nonalcoholic steatohepatitis, according to speaker at an Inventiva web conference.“Lanifibranor (1,200 mg) met the primary endpoints with a statistically significant reduction, after 6 months of treatment, of the Steatosis Activity Fibrosis score, which combines assessments of hepatocellular inflammation and ballooning, with no worsening in intention to treat and per protocol populations,” Pierre Broqua, PhD, chief scientific officer and cofounder of Inventiva, said during hisRead More

Share on facebook
Share on twitter
Share on linkedin